Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alza Concerta 72 Mg Dose "Approvable"; Would Be Highest Once-Daily Methylphenidate Dose

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA also gives conditional nod to use in adolescents. Highest recommended daily dose for competitors such as Ritalin SR and Metadate CD is 60 mg. The 72 mg dose will be achieved via combination of existing-strength tablets.

You may also be interested in...



Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal

Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.

Pozen’s Migraine Agent To Be Focus Of FDA Advisory Committee Review

Naproxen/metoclopramide combination is expected to be reviewed by the Peripheral & Central Nervous System Drugs Advisory Committee May 4. Potential risk of tardive dyskinesia is expected to be discussed. FDA deemed MT-100 “not approvable” earlier this year.

Takeda Files Actos/Metformin Combination Actoplus Met For Type 2 Diabetes

NDA submission of pioglitazone/metformin combo marks beginning of Takeda’s expansion in the U.S. diabetes market; the firm has insulin resistance-improving agents in Phase II and Phase III.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel